|Bid||6.33 x 1100|
|Ask||6.34 x 2200|
|Day's Range||6.19 - 6.39|
|52 Week Range||5.89 - 17.05|
|Beta (3Y Monthly)||0.70|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The big shareholder groups in Dynavax Technologies Corporation (NASDAQ:DVAX) have power over the company. Large...
A non-biotech investor would think FDA approval is the biggest hurdle for most small biotech companies and would be rewarded by the market. This is why so many small biotech stocks frequently decline in the quarters following the initial euphoria of FDA approval. This is why initial drug rollouts are usually slower and consume more cash that investors expect after the FDA green light is granted.
How do we determine whether Dynavax Technologies Corporation (NASDAQ:DVAX) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 7.46% and -3.94%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Berkeley, California-based company said it had a loss of 62 cents per share. The biopharmaceutical company posted revenue of $5.8 million in the period. Dynavax Technologies shares have fallen 29% ...
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But l...
EmeryStation West is the latest building in Wareham Development's 2 million-square-foot complex in Emeryville.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 1) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...
Anyone researching Dynavax Technologies Corporation (NASDAQ:DVAX) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory.Read More...
How far off is Dynavax Technologies Corporation (NASDAQ:DVAX) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is Read More...
After a brutal fourth quarter to close out 2018, equities have started out on the right foot so far in 2019. Some soothing words from the Federal Reserve have helped the action in recent trading sessions, as has some progress on the trade talks between China and the United States. Helping tremendously are rallies in beaten-down sectors within the market.
After extended weakness, biotech stocks turned a corner along with the broader markets to close out the week. With just a session left, it looks less likely the sector ends in the black for the year. The ...
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Carl Icahn and George Soros think. Those hedge fund operators make billions of dollars each […]